Biodesix (NASDAQ:BDSX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01, Zacks reports. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The business had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million. Biodesix updated its FY 2025 guidance to EPS.
Biodesix Stock Down 10.1 %
BDSX opened at $0.71 on Tuesday. Biodesix has a fifty-two week low of $0.70 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The company has a market capitalization of $103.72 million, a P/E ratio of -1.83 and a beta of 1.06. The stock has a fifty day moving average of $1.12 and a 200-day moving average of $1.42.
Insider Activity at Biodesix
In other news, CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 128,702 shares of company stock valued at $118,406 over the last quarter. 69.20% of the stock is owned by corporate insiders.
About Biodesix
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Read More
- Five stocks we like better than Biodesix
- What is Put Option Volume?
- Warren Buffett Sold ULTA Stock—But Should You?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Actively Managed ETFs Outperforming Despite Their Higher Fees
- Insider Trades May Not Tell You What You Think
- Monster Beverage: Monster Upside or a Risky Buy?
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
